119 related articles for article (PubMed ID: 38345887)
21. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
[TBL] [Abstract][Full Text] [Related]
22. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography.
Kim HK; Choi YS; Kim K; Shim YM; Park K; Ahn YC; Lee KS; Choi JY; Kim J
J Thorac Oncol; 2011 Feb; 6(2):336-42. PubMed ID: 21164366
[TBL] [Abstract][Full Text] [Related]
24. Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment.
Stamatis G; Müller S; Weinreich G; Schwarz B; Eberhardt W; Pöttgen C; Aigner C
Eur J Cardiothorac Surg; 2022 Jan; 61(2):269-276. PubMed ID: 34368849
[TBL] [Abstract][Full Text] [Related]
25. Survival outcome of upfront surgery for clinical single-station N2 non-small cell lung cancer.
Hayakawa T; Isaka M; Konno H; Mizuno T; Kawata T; Kenmotsu H; Takahashi T; Ohde Y
Jpn J Clin Oncol; 2023 Apr; 53(5):429-435. PubMed ID: 36655315
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
27. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
Matsunaga T; Suzuki K; Takamochi K; Oh S
Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
[TBL] [Abstract][Full Text] [Related]
28. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
[No Abstract] [Full Text] [Related]
29. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
30. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
[TBL] [Abstract][Full Text] [Related]
31. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
[TBL] [Abstract][Full Text] [Related]
32. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
33. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
[TBL] [Abstract][Full Text] [Related]
34. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy.
Voltolini L; Luzzi L; Ghiribelli C; Paladini P; Di Bisceglie M; Gotti G
Eur J Cardiothorac Surg; 2001 Dec; 20(6):1106-12. PubMed ID: 11717012
[TBL] [Abstract][Full Text] [Related]
35. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
36. Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy.
İşgörücü Ö; Citak N
Thorac Cardiovasc Surg; 2023 Apr; 71(3):206-213. PubMed ID: 35235990
[TBL] [Abstract][Full Text] [Related]
37. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.
Ichinose Y; Kato H; Koike T; Tsuchiya R; Fujisawa T; Shimizu N; Watanabe Y; Mitsudomi T; Yoshimura M; Tsuboi M;
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):803-8. PubMed ID: 11581617
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
Evison M; Edwards T; Balata H; Tempowski A; Teng B; Bishop P; Fontaine E; Krysiak P; Rammohan K; Shah R; Crosbie P; Booton R
Lung Cancer; 2018 Jan; 115():127-130. PubMed ID: 29290254
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Lorent N; De Leyn P; Lievens Y; Verbeken E; Nackaerts K; Dooms C; Van Raemdonck D; Anrys B; Vansteenkiste J;
Ann Oncol; 2004 Nov; 15(11):1645-53. PubMed ID: 15520066
[TBL] [Abstract][Full Text] [Related]
40. Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
Casiraghi M; Guarize J; Sandri A; Maisonneuve P; Brambilla D; Romano R; Galetta D; Petrella F; Gasparri R; Gridelli C; De Marinis F; Spaggiari L
Clin Lung Cancer; 2019 Mar; 20(2):97-106.e1. PubMed ID: 30446406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
